Acarbose Treatment Increases Serum Total Adiponectin Levels in Patients with Type 2 Diabetes

この論文にアクセスする

この論文をさがす

著者

    • OCHIAI HIROMI
    • Third Department of Medicine, Teikyo University Chiba Medical Center
    • OOKA HIKARI
    • Third Department of Medicine, Teikyo University Chiba Medical Center
    • SHIDA CHIHO
    • Third Department of Medicine, Teikyo University Chiba Medical Center
    • ISHIKAWA TOSHIO
    • Third Department of Medicine, Teikyo University Chiba Medical Center
    • INOUE DAISUKE
    • Third Department of Medicine, Teikyo University Chiba Medical Center
    • OKAZAKI RYO
    • Third Department of Medicine, Teikyo University Chiba Medical Center

抄録

Adiponectin is an anti-diabetic and anti-atherogenic adipokine that serves as a major determinant of insulin sensitivity. Thiazolidine derivatives increase circulating adiponectin, particularly the high molecular weight isoform, which has been shown to well correlate with amelioration of insulin resistance by thiazolidines in diabetic patients. α-glucosidase inhibitors are another class of anti-diabetic agents that specifically reduce postprandial blood glucose elevations, but its effect on adiponectin is largely unknown. In the present study we investigated effect of an α-glucosidase inhibitor, acarbose, together with pioglitazone, the only thiazolidine derivative available in Japan, on serum concentrations of adiponectin. Seventeen patients with type 2 diabetes were treated with acarbose and sixteen with pioglitazone for three months. Treatment with acarbose and pioglitazone decreased HbA1c values by 0.49% and 0.63%, respectively. Pioglitazone, as expected, increased serum levels of total adiponectin by 2.1 fold and its high molecular weight isoform by 3.6 fold. We found that acarbose also caused a small but significant increase in serum concentrations of total adiponectin. However, in contrast to pioglitazone, no appreciable changes were observed in the levels of high molecular weight adiponectin. In conclusion, acarbose increases serum concentrations of total adiponectin without preference of the high molecular weight isoform in type 2 diabetic patients. Clinical relevance of the increased adiponectin to the acarbose effects remains to be elucidated.<br>

収録刊行物

  • Endocrine journal  

    Endocrine journal 55(3), 549-556, 2008-06-01 

    The Japan Endocrine Society

参考文献:  37件

参考文献を見るにはログインが必要です。ユーザIDをお持ちでない方は新規登録してください。

被引用文献:  2件

被引用文献を見るにはログインが必要です。ユーザIDをお持ちでない方は新規登録してください。

各種コード

  • NII論文ID(NAID)
    10021266527
  • NII書誌ID(NCID)
    AA10901436
  • 本文言語コード
    ENG
  • 資料種別
    ART
  • ISSN
    09188959
  • データ提供元
    CJP書誌  CJP引用  J-STAGE 
ページトップへ